Efficacy and safety of midodrine in the treatment of dialysis-associated hypotension.
Dialysis-associated hypotension is a morbid problem in haemodialysis patients. Employment of midodrine at the start of dialysis has reduced the severity and frequency of hypotensive episodes in these patients. Through selective alpha(1)-adrenergic receptor-binding, desglymidodrine, the active metabolite of midodrine, raises blood pressure by enhancing venous and arterial tone. This medication has been demonstrated to be effective and safe in the acute and chronic treatment of haemodialysis-associated hypotension in end stage renal disease patients.
Perazella
Mark A
MA
Section of Nephrology, Department of Medicine, Yale University School of Medicine, LMP 2071, 333 Cedar Street, New Haven, CT 06520-8029, USA. mark.perazella@yale.edu
D000818:Animals; D001291:Attitude of Health Personnel; D001794:Blood Pressure / Q000187:drug effects; D015897:Comorbidity; D006801:Humans; D007022:Hypotension / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology; D008879:Midodrine / Q000737:chemistry / Q000627:therapeutic use*; D009017:Morbidity; D006435:Renal Dialysis / Q000009:adverse effects*; D012306:Risk; D014662:Vasoconstrictor Agents / Q000627:therapeutic use*
D014662:Vasoconstrictor Agents; D008879:Midodrine